<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393025</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU MD 142/2016</org_study_id>
    <nct_id>NCT04393025</nct_id>
  </id_info>
  <brief_title>Endovascular Stenting of Medically Refractory ICASD (Clinical and Sonographic Study)</brief_title>
  <acronym>VasIntervent</acronym>
  <official_title>Endovascular Stenting of Medically Refractory Intracranial Arterial Stenotic (ICAS) Disease (Clinical and Sonographic Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral Endovascular Stenting of medically refractory Intracranial Stenotic Blood Vessels
      with Recurrent Ischemic Strokes patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty patients were enrolled with 25 underwent Intracranial Stenting 25 received optimal
      medicall treatment without stenting and comparative study of primary outcome was conducted
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two armed medical study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement of IC stented patients in comparison to medically treated</measure>
    <time_frame>3 months</time_frame>
    <description>clinical assessment by National Institute of Health Stroke Scale (NIHSS) for clinical impr</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional improvement of IC stented patients in comparison to medically treated</measure>
    <time_frame>3 months</time_frame>
    <description>Functional assessment by modified Rankin Scale (mRS) for functional improvement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood flow velocity accrossed Stenotic Large IC Vessels in comparison to medically treated</measure>
    <time_frame>3 months</time_frame>
    <description>Transcranial doppler (TCD) assessment of Mean Flow Velocity (MFV) across IC vessels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>No Recurrent Ischemic stroke in stented ICSD patients</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical Assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>Intracranial Stenting</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>25 Patients presented with recurrent Ischemic CVS with Large ICSD received ICS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin+Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 Patients presented with recurrent Ischemic CVS with Large ICSD received optimal medical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intracranial Stenting by Intracranial Stent Device</intervention_name>
    <description>Large Intracranial Vessels with ICSD underwent catheter lab and IC stent is inserted</description>
    <arm_group_label>Intracranial Stenting</arm_group_label>
    <other_name>cardiac and wingspan IC stent device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimum medical treatment</intervention_name>
    <description>Optimum Medical treatment</description>
    <arm_group_label>Aspirin+Clopidogrel</arm_group_label>
    <other_name>Clopidogrel 75 mg +Aspirin 161 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients age between 30-80 years.

          2. Symptomatic ICAS: presented with TIA or stroke, attributed to 70%-99% stenosis of a
             major intracranial artery: Internal carotid artery (ICA), middle cerebral artery (MCA)
             [M1segment], vertebral artery (VA), or basilar artery (BA).

          3. Patient with recurrent TIA or stroke despite medical therapy, including
             anti-coagulation or antiplatelet and control of all vascular risk factors (DM, HTN and
             Hyperlipidemia).

        Exclusion Criteria:

          1. Patients previously stented at the target lesion or had extracranial stenosis.

          2. Patient with acute stroke (within two weeks from the onset).

          3. Complete occlusion of the artery on the imaging assessment.

          4. Massive cerebral infarction (more than half the MCA territory), intracranial
             hemorrhage, epidural or subdural hemorrhage, and intracranial brain tumor on CT or MRI
             scans.

          5. Contraindications to antithrombotic and/or anticoagulant therapies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed Ahmed Shafik Abdallah</investigator_full_name>
    <investigator_title>Clinical professor of Neurology-Faculty of Medicine-ASU</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

